



Prof. Martin N. Pruschy

Laboratory for Molecular
Radiobiology
Dept. Radiation Oncology
University Hospital Zurich
Raemistr. 100,
CH-8091 Zürich

044-2558549 (voice)
044-2554435 (fax)
martin.pruschy@usz.ch
[http://www.cnz.uzh.ch/Research/
RG3/Pruschy.html](http://www.cnz.uzh.ch/Research/RG3/Pruschy.html)

POSITION

Since 1997: Head of Research Unit for Molecular Radiobiology, Dept. Radiation Oncology,
University Hospital Zurich: Translational Research in Radiation Biology/Oncology.

EDUCATION, ACADEMIC POSITION

December 2006	Professor for Molecular Radiobiology (<i>Extraordinariat</i>), Univ. of Zurich
January 2006/2012	Visiting Professor Rambam Medical Center and Technion, Haifa-Israel
2003	Habilitation/Privatdozent (Venia Legendi for Translational Research in Oncology) at the University of Zurich
1989 -1993	PhD-Dissertation at the Swiss Federal Institute of Technology

POSTDOCTORAL TRAINING

1996 - 1997	University of Zurich, Dept. of Radiation Oncology (Prof. U.M. Lütolf).
1993 - 1995	Harvard University, Dept. of Chemistry (Prof. S. Schreiber)

EXECUTIVE POSITIONS IN SCIENTIFIC ORGANISATIONS

Member of Scientific Committee (WiKo), Krebsliga Schweiz
Member of Scientific Committee Radiobiology, ESTRO
Board of Trustees Center for Clinical Research, University Zurich

REVIEWER

Journals: Clin Cancer Research; Oncogene; Brit. J. Cancer; BBRC; BLOOD; Breast Cancer;
FEBS Letters; CMC-Anticancer Agents; Pharmaceutical Research, Int. J. Radiat. Biol.; Int.
J. Radiat. Onc. Biol. Phys.; Radiotherapy and Oncology

Grants: Swiss/German/Austrian National Foundation, Swiss/German Cancer League, The Wellcome
Trust, UK; AICR, UK

AWARDS

Novartis Research Award 2008: Dynamics of Tumor Hypoxia in Response to Different Treatment
Modalities
VARIAN Recognition Award 2002 of Switzerland: The Combined Treatment Modality of Ionizing
Radiation with Antisignaling Agents

COMPETITIVE RESEARCH GRANTS (2006-2012)

Swiss National Foundation (SNF), Swiss cancer League, Vontobel Stiftung, Stiftung wissenschaftliche
Forschung University Zurich, EMDO-Stiftung, Sassella Foundation, Novartis Foundation, Hartmann
Müller Stiftung, Wolf-Stiftung

MARTIN PRUSCHY, Prof. Dr. sc. nat.

(complete publication list: <http://www.radio-onkologie.usz.ch/LehreUndForschung/Laborforschung/MolBioLabor/Seiten/Publications.aspx>)

5 most important original publications (2012-2002)

1. Broggini-Tenzer A, Vuong V, Pruschy M.
Metabolism of tumors under treatment: mapping of metabolites with quantitative bioluminescence.
Radiother Oncol. 2011 Jun;99(3):398-403.
I.F. 4.337
2. Bley CR, Jochum W, Orlowski K, Furmanova P, Vuong V, McSheehy PM, Pruschy M. (2009).
Role of the microenvironment for radiosensitization by patupilone.
Clin Cancer Res. 15:1335-42.
I.F. 7.338
3. Oliver Riesterer, Michael Honer, Wolfram Jochum, Christoph Oehler, Simon Ametamey and Martin Pruschy (2006)
Ionizing radiation antagonizes tumor hypoxia induced by anti-angiogenic treatment.
Clinical Cancer Research, 12, 3518-3524
I.F. 7.338
4. Barbara Hofstetter, Van Vuong, Angela Broggini-Tenzer, Stephan Bodis, Ilja F. Ciernik, Dorian Fabbro, Markus Wartmann, Gerd Folkers and Martin Pruschy (2005)
Patupilone (EPO906) Acts as Radiosensitizing Agent in Multidrug-Resistant Cancer Cells in Vitro and in Vivo.
Clinical Cancer Research, 11, 1588-1596
I.F. 7.338
5. Daniel Zingg, Oliver Riesterer, Christoph Glanzmann, Stephan Bodis and Martin Pruschy (2004).
Differential Activation of the PI3K/Akt-Survival Pathway by Ionizing Radiation in Tumor and Primary Endothelial Cells.
Cancer Research, 64, 5398-5406
I.F. 8.234